Our investments


Symetis, founded in January 2001 as a spin-off from the University of Zurich, is a Swiss company developing new transcatheter aortic valve implantation (TAVI) systems.

The company’s products, ACURATE TA™ and ACURATE neo™ and their delivery systems, based on proprietary design and delivery technologies, are marketed and sold in key markets in Europe and in other markets, and are well positioned to target the constantly growing TAVI market. Dr Philippe Pouletty is a Board member.